论文部分内容阅读
目的:观察鲜竹沥口服液辅助治疗慢性阻塞性肺疾病(COPD)急性发作的临床疗效。方法:将COPD急性发作期患者118例随机分为对照组和研究组各59例。对照组予常规护理及西医对症治疗,研究组在对照组的基础上予鲜竹沥口服液治疗。观察2组治疗前后动脉血气分析指标氧分压(Pa O_2)、二氧化碳分压(Pa CO_2),肺功能指标第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC,血清C-反应蛋白(CRP)及临床疗效。结果:总有效率研究组为94.9%,对照组为83.1%,2组比较,差异有统计学意义(P<0.05)。治疗后2组Pa O_2均较治疗前升高(P<0.05),Pa CO_2、CRP较治疗前降低(P<0.05);且研究组上述指标改善较对照组更显著(P<0.05)。治疗后2组FEV1、FEV1/FVC均较治疗前升高(P<0.05),且研究组上述指标改善较对照组更显著(P<0.05)。2组FVC治疗前后比较,差异无统计学意义(P>0.05)。结论:中西医结合鲜竹沥口服液辅助治疗COPD急性发作能提高临床疗效,值得临床推广应用。
Objective: To observe the clinical curative effect of Xianzhuliu oral liquid in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods: 118 patients with acute exacerbation of COPD were randomly divided into control group and study group of 59 cases. The control group was given routine nursing and western medicine symptomatic treatment. The study group was treated with Xianzhuli Oral Liquid on the basis of the control group. The arterial blood gas analysis indexes Pa O 2, Pa CO 2, FEV 1, FVC, FEV 1 / FVC and serum before and after treatment were observed before and after treatment. C-reactive protein (CRP) and clinical efficacy. Results: The total effective rate was 94.9% in the study group and 83.1% in the control group. There was significant difference between the two groups (P <0.05). After treatment Pa 2 was higher than before treatment (P <0.05), PaCO 2, CRP was lower than before treatment (P <0.05); and the above indicators in the study group improved more significantly than the control group (P <0.05). After treatment, FEV1 and FEV1 / FVC in both groups were significantly higher than those before treatment (P <0.05), and the improvement of the above indexes in the study group was more significant than that in the control group (P <0.05). There was no significant difference between the two groups before and after treatment of FVC (P> 0.05). Conclusion: The combination of TCM and WM Xianchu Li oral liquid adjuvant treatment of acute exacerbation of COPD can improve the clinical efficacy, it is worthy of clinical promotion and application.